TRIAL DATA
Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology
. This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans.
What this means
If you have a KRAS G12C mutation, a simple blood test during treatment may help your care team know sooner whether your therapy is working. This could lead to faster adjustments if needed.